文献速递急性肾损伤

右美托咪定减少去甲肾上腺素需求并改善绵羊脓毒症急性肾损伤的肾髓质氧合与功能

Dexmedetomidine reduces norepinephrine requirements and preserves renal oxygenation and function in ovine septic acute kidney injury.
PubMed 文献 · Kidney Int · 2019-07-10

在绵羊革兰阴性脓毒症急性肾损伤模型中,去甲肾上腺素加重肾髓质缺氧。结果显示右美托咪定联合去甲肾上腺素可显著减少去甲肾上腺素剂量(从0.8降至0.4 μg/kg/min),减轻髓质低灌注和缺氧,并改善肌酐清除率。

要点

  • 脓毒症导致平均动脉压、髓质灌注、髓质组织氧分压和肌酐清除率显著下降。
  • 去甲肾上腺素虽恢复平均动脉压,但加重髓质低灌注和缺氧。
  • 右美托咪定联合去甲肾上腺素减少去甲肾上腺素需求并改善髓质氧合和肾功能。

核心结论

  • 在实验性脓毒症急性肾损伤中,右美托咪定减少去甲肾上腺素需求,减轻其对肾髓质的不良影响,并维持肾功能。

研究设计与样本

  • 绵羊革兰阴性脓毒症模型,随机分为四组(去甲肾上腺素、去甲肾上腺素联合右美托咪定、单用右美托咪定、生理盐水对照),每组8只,干预从脓毒症24小时至30小时。

主要发现

  • 脓毒症显著降低平均动脉压(84降至67 mmHg)、平均肾髓质灌注(1250降至730灌注单位)、平均髓质组织氧分压(40降至21 mmHg)和肌酐清除率(2.50降至0.78 mL/kg/min)。
  • 去甲肾上腺素恢复基线平均动脉压(至83 mmHg),但加重髓质低灌注(至330灌注单位)和髓质缺氧(至9 mmHg)。
  • 右美托咪定(0.5 μg/kg/h)联合去甲肾上腺素显著减少恢复基线平均动脉压所需的去甲肾上腺素剂量(0.8降至0.4 μg/kg/min),减轻髓质低灌注(至606灌注单位)和髓质组织缺氧(至29 mmHg),并逐渐增加肌酐清除率(至1.8 mL/kg/min)。
  • 与生理盐水时间对照相比,单用右美托咪定显著防止平均动脉压随时间下降,但对髓质灌注、氧合或肌酐清除率无显著影响。

临床怎么用

  • 在脓毒症急性肾损伤中,右美托咪定可作为辅助用药减少去甲肾上腺素用量并减轻其肾髓质缺氧副作用。

局限性

  • 本研究为绵羊实验模型,结果需临床研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Norepinephrine exacerbates renal medullary hypoxia in experimental septic acute kidney injury. Here we examined whether dexmedetomidine, an α2-adrenergic agonist, can restore vasopressor responsiveness, decrease the requirement for norepinephrine and attenuate medullary hypoxia in ovine gram-negative sepsis. Sheep were instrumented with pulmonary and renal artery flow probes, and laser Doppler and oxygen-sensing probes in the renal cortex and medulla. Conscious sheep received an infusion of live Escherichia coli for 30 hours. Eight sheep in each group were randomized to receive norepinephrine, norepinephrine with dexmedetomidine, dexmedetomidine alone or saline vehicle, from 24-30 hours of sepsis. Sepsis significantly reduced the average mean arterial pressure (84 to 67 mmHg), average renal medullary perfusion (1250 to 730 perfusion units), average medullary tissue pO2 (40 to 21 mmHg) and creatinine clearance (2.50 to 0.78 mL/Kg/min). Norepinephrine restored baseline mean arterial pressure (to 83 mmHg) but worsened medullary hypoperfusion (to 330 perfusion units) and medullary hypoxia (to 9 mmHg). Dexmedetomidine (0.5 μg/kg/h) co-administration significantly reduced the norepinephrine dose (0.8 to 0.4 μg/kg/min) required to restore baseline mean arterial pressure, attenuated medullary hypoperfusion (to 606 perfusion units), decreased medullary tissue hypoxia (to 29 mmHg), and progressively increased creatinine clearance (to 1.8 mL/Kg/min). Compared with vehicle time-control, dexmedetomidine given alone significantly prevented the temporal reduction in mean arterial pressure, but had no significant effects on medullary perfusion and oxygenation or creatinine clearance. Thus, in experimental septic acute kidney injury, dexmedetomidine reduced norepinephrine requirements, attenuated its adverse effects on the renal medulla, and maintained renal function.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Lankadeva YR, Ma S, Iguchi N, et al. Dexmedetomidine reduces norepinephrine requirements and preserves renal oxygenation and function in ovine septic acute kidney injury. Kidney Int. 2019. PMID: 31530477. doi:10.1016/j.kint.2019.06.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。